- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | ProKidney GAAP EPS of -$0.15 misses by $0.01, revenue of $0.15M in-line | 1 | Seeking Alpha | ||
| 10.08. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.08. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.06. | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel's Accelerated Approval Path | 1 | Insider Monkey | ||
| 02.06. | ProKidney beruft Kenneth Locke zum Chief Technical Officer | 2 | Investing.com Deutsch | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 02.06. | ProKidney Appoints Kenneth Locke as Chief Technical Officer | 205 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| 18.05. | ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M | 1 | Seeking Alpha | ||
| 15.05. | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 15.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | 403 | GlobeNewswire (Europe) | On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase... ► Artikel lesen | |
| 15.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 25.03. | ProKidney names Greg Madison as chief commercial officer | 2 | Investing.com | ||
| 25.03. | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | 291 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney... ► Artikel lesen | |
| 18.03. | BofA reiterates ProKidney stock Underperform rating at $1 target | 2 | Investing.com | ||
| 18.03. | BofA bestätigt "Underperform"-Rating für ProKidney mit Kursziel von 1 US-Dollar | 3 | Investing.com Deutsch | ||
| 18.03. | ProKidney GAAP EPS of -$0.52 beats by $0.18, revenue of $0.89M beats by $0.35M | 1 | Seeking Alpha | ||
| 18.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.11.25 | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 348 | GlobeNewswire (Europe) | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| HEIDELBERG PHARMA | 2,610 | +1,16 % | EQS-News: Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Studie
Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie... ► Artikel lesen | |
| NANOREPRO | 1,655 | -2,07 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
18.08.2026 / 07:30... ► Artikel lesen | |
| VIVOSIM LABS | 0,286 | +0,25 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,228 | +2,24 % | BioNxt erreicht wichtigen Meilenstein im klinischen Cladribin-Programm für MS mit Abschluss des IMPD vor Beginn der klinischen Studien am Menschen | VANCOUVER, BC / ACCESS Newswire /
26. August 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| GENMAB | 289,00 | +1,01 % | Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,27 % bei einem Aktienkurs von 1,835 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.